Identification and validation of a threshold for early posttransplant bronchoalveolar fluid hyaluronan that distinguishes lung recipients at risk for chronic lung allograft dysfunction

被引:0
|
作者
Todd, Jamie L. [1 ,2 ]
Weber, Jeremy M. [2 ]
Kelly, Francine L. [1 ]
Nagler, Andrew [1 ]
Mcarthur, Patrick
Eason, Lerin [1 ]
Rim, Jeeyon G. [1 ]
Frankel, Courtney W. [1 ]
Belperio, John A. [3 ]
Budev, Marie [4 ]
Martinu, Tereza [5 ,6 ,7 ]
Patel, Kunal [8 ]
Reynolds, John M. [1 ]
Shah, Pali D. [9 ]
Singer, Lianne G. [5 ,6 ,7 ]
Snyder, Laurie D. [1 ,2 ]
Tsuang, Wayne [4 ]
Weigt, S. Sam [3 ]
Neely, Megan L. [2 ,10 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Durham, NC USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
[4] Cleveland Clin, Dept Med, Cleveland, OH USA
[5] Univ Hlth Network, Dept Med, Toronto, ON, Canada
[6] Univ Toronto, Dept Med, Toronto, ON, Canada
[7] Univ Hlth Network, Ajmera Transplant Ctr, Toronto Lung Transplant Program, Toronto, ON, Canada
[8] Duke Univ, Med Ctr, Dept Surg, Durham, NC USA
[9] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[10] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA
来源
基金
美国国家卫生研究院;
关键词
lung transplantation; chronic lung allograft dysfunction; hyaluronan; bronchoalveolar lavage fluid;
D O I
10.1016/j.healun.2024.10.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Few tools exist for the early identification of patients at risk for chronic lung allograft dysfunction (CLAD). We previously showed hyaluronan (HA), a matrix molecule that regulates lung inflammation and fibrosis, accumulates in bronchoalveolar lavage fluid (BALF) and blood in CLAD. We aimed to determine if early posttransplant HA elevations inform CLAD risk. METHODS: HA was quantified in 3,080 BALF and 1,323 blood samples collected over the first posttransplant year in 743 adult lung recipients at 5 centers. The relationship between BALF or blood HA and CLAD was assessed using Cox models with a time-dependent binary covariate for "elevated" HA. Potential thresholds for elevated HA were examined using a grid search between the 50th and 85th percentile. The optimal threshold was identified using fit statistics, and the association between the selected threshold and CLAD was internally validated through iterative resampling. A multivariable Cox model using the selected threshold was performed to evaluate the association of elevated HA with CLAD, considering other factors that may influence CLAD risk. RESULTS: BALF HA levels > 19.1 ng/ml (65th percentile) had the largest hazard ratio (HR) for CLAD (HR 1.70, 95% confidence interval [CI] 1.25-1.31; p < 0.001), optimized fit statistics, and demonstrated robust reproducibility. In a multivariable model, the occurrence of BALF HA > 19.1 ng/ml in the first posttransplant year conferred a 66% increase in the hazards for CLAD (adjusted HR 1.66, 95% CI 1.19-2.32; p = 0.003). Blood HA was not significantly associated with CLAD. CONCLUSIONS: We identified and validated a precise threshold for BALF HA in the first post- transplant year that distinguishes patients at increased CLAD risk. J Heart Lung Transplant 2025;44:320-328 (c) 2024 International Society for Heart and Lung Transplantation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:320 / 328
页数:9
相关论文
共 50 条
  • [1] Early Posttransplant Bronchoalveolar Lavage Fluid (BALF) Hyaluronan is an Independent Risk Marker for Chronic Lung Allograft Dysfunction (CLAD)
    Rim, J.
    Weber, J.
    Neely, M.
    Kelly, F.
    Nagler, A.
    Eason, L.
    McArthur, P.
    Belperio, J.
    Budev, M.
    Reynolds, J.
    Shah, P.
    Singer, L.
    Snyder, L.
    Palmer, S.
    Todd, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S48 - S49
  • [2] Bronchoalveolar Lavage Fluid Proteome in Chronic Lung Allograft Dysfunction
    Todd, J. L.
    Venkat, V.
    Henao, R.
    Brinkley, C.
    Kelly, F. L.
    Frankel, C. W.
    Frear, A.
    Moseley, M. A.
    Thompson, J. W.
    Belperio, J. A.
    Budev, M.
    Shah, P. D.
    Singer, L. G.
    Reynolds, J. M.
    Foster, M. W.
    Palmer, S. M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S204 - S204
  • [3] Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients
    DerHovanessian, Ariss
    Todd, Jamie L.
    Zhang, Alice
    Li, Ning
    Mayalall, Aradhna
    Copeland, C. Ashley Finlen
    Shino, Michael
    Pavlisko, Elizabeth N.
    Wallace, W. Dean
    Gregson, Aric
    Ross, David J.
    Saggar, Rajan
    Lynch, Joseph P., III
    Belperio, John
    Snyder, Laurie D.
    Palmer, Scott M.
    Weigt, S. Sam
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (05) : 627 - 635
  • [4] Oesophageal stasis is a risk factor for chronic lung allograft dysfunction and allograft failure in lung transplant recipients
    Ramendra, Rayoun
    Fernandez-Castillo, Juan C.
    Huszti, Ella
    Ghany, Rasheed
    Aversa, Meghan
    Havlin, Jan
    Riddell, Peter
    Chaparro, Cecilia M.
    Singer, Lianne G.
    Liu, Louis
    Keshavjee, Shaf
    Yeung, Jonathan C.
    Martinu, Tereza
    ERJ OPEN RESEARCH, 2023, 9 (05)
  • [5] Bronchoalveolar Lavage Lipopolysaccharide is Associated with Aspiration, Acute Rejection, and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
    Ramendra, R.
    Havlin, J.
    Levy, L.
    Zhang, K.
    Ahmed, M.
    Singer, L.
    Todd, J.
    Weigt, S.
    Yeung, J.
    Sage, A.
    Keshavjee, S.
    Martinu, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S139 - S139
  • [6] Chronic Lung Allograft Dysfunction Is Associated with Increased Levels of Cell-Free Mitochondrial DNA in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients
    Schneck, Emmanuel
    Askevold, Ingolf
    Rath, Ramona
    Hecker, Andreas
    Reichert, Martin
    Guth, Stefan
    Koch, Christian
    Sander, Michael
    Seeger, Werner
    Mayer, Konstantin
    Padberg, Winfried
    Sommer, Natascha
    Kuhnert, Stefan
    Hecker, Matthias
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [7] Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers
    Tissot, Adrien
    Danger, Richard
    Claustre, Johanna
    Magnan, Antoine
    Brouard, Sophie
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [8] Air Pollution and the Development of Posttransplant Chronic Lung Allograft Dysfunction
    Bhinder, S.
    Chen, H.
    Sato, M.
    Copes, R.
    Evans, G. J.
    Chow, C. -W.
    Singer, L. G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (12) : 2749 - 2757
  • [9] Simkania negevensis and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
    Aguilar, C.
    Li, Y.
    Martinu, T.
    Tikkanen, J.
    Kent, W.
    Juvet, S.
    Humar, A.
    Kumar, D.
    Kolls, J. K.
    Keshavjee, S.
    Singer, L. G.
    Husain, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S176 - S176
  • [10] Early posttransplant reductions in club cell secretory protein associate with future risk for chronic allograft dysfunction in lung recipients: results from a multicenter study
    Todd, Jamie L.
    Weber, Jeremy M.
    Kelly, Francine L.
    Neely, Megan L.
    Nagler, Andrew
    Carmack, Dylan
    Frankel, Courtney W.
    Brass, David M.
    Belperio, John A.
    Budev, Marie M.
    Hartwig, Matthew G.
    Martinu, Tereza
    Reynolds, John M.
    Shah, Pali D.
    Singer, Lianne G.
    Snyder, Laurie D.
    Weigt, S. Sam
    Palmer, Scott M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (06): : 741 - 749